NANOPHARM LIMITED
Get an alert when NANOPHARM LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£2.3k
-99.1% lowest in 6 filed years
Net assets
£524k
-70.3% lowest in 6 filed years
Employees
76
0% vs 2024
Profit before tax
-£1.8m
+34.1% vs 2024
Net assets
6-year trend · vs Health Care median
Accounts
6-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|---|---|---|
| Turnover | — | — | £5,865,408 | £7,486,864 | £8,528,227 | £9,053,308 | +6.2% | |
| Operating profit | — | — | £188,808 | -£919,654 | -£2,633,361 | -£1,571,812 | +40.3% | |
| Profit before tax | — | — | £204,294 | -£893,790 | -£2,757,798 | -£1,817,484 | +34.1% | |
| Net profit | — | — | £89,549 | -£711,620 | -£3,256,298 | -£1,241,325 | +61.9% | |
| Cash | £1,799,729 | £1,339,469 | £670,751 | £54,224 | £246,713 | £2,294 | -99.1% | |
| Total assets less current liabilities | £4,766,888 | £5,929,252 | £6,133,546 | £5,239,755 | £2,481,957 | £1,328,139 | -46.5% | |
| Net assets | £4,635,690 | £5,643,769 | £5,733,318 | £5,021,698 | £1,765,400 | £524,075 | -70.3% | |
| Equity | £4,635,690 | £5,643,769 | £5,733,318 | £5,021,698 | £1,765,400 | £524,075 | -70.3% | |
| Average employees | 39 | 49 | 59 | 74 | 76 | 76 | 0% | |
| Wages | — | — | £2,137,840 | £3,082,632 | £3,948,122 | £4,093,632 | +3.7% | |
| Directors' remuneration | — | — | £110,315 | £56,060 | — | £70,459 | — | |
| Directors' pension contributions | — | — | — | — | — | £6,003 | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|---|
| Operating margin | — | — | 3.2% | -12.3% | -30.9% | -17.4% | |
| Net margin | — | — | 1.5% | -9.5% | -38.2% | -13.7% | |
| Return on capital employed | — | — | 3.1% | -17.6% | -106.1% | -118.3% | |
| Gearing (liabilities / total assets) | 11.4% | 13.0% | 17.4% | 33.0% | 77.9% | 94.5% | |
| Current ratio | — | — | — | — | 0.70x | 0.51x | |
| Interest cover | — | — | — | — | -20.81x | -6.31x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Xeinaadin Audit Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future.”
Significant events
- “In Q1 2026 Nanopharm successfully completed its first general MHRA inspection and obtained GMP certification for its analytical services.”
- “Following completion of an internal project to develop intranasal GLP-1s and the filing of 3 patents in 2024/5, a more extensive internal R&D program to develop inhaled biologics was initiated in 2025.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 11 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| PEARSON, Douglas John | Secretary | 2019-06-05 | — | — |
| BROUET, Guillaume | Director | 2019-06-05 | Apr 1967 | French |
| BUDD, Gemma Louise | Director | 2025-09-25 | Aug 1988 | British |
Show 11 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| CLEMENT, Mark Rowland | Secretary | 2019-01-03 | 2019-06-05 |
| PRICE, Robert, Prof | Secretary | 2002-02-13 | 2007-09-30 |
| WAYNE, Harold | Nominee Secretary | 2002-02-11 | 2002-02-11 |
| M S BATH SECRETARIES LIMITED | Corporate Secretary | 2007-09-30 | 2019-01-03 |
| CLEMENT, Mark Rowland | Director | 2016-09-01 | 2019-01-07 |
| HALL, Christopher Maxwell | Director | 2019-06-05 | 2025-07-21 |
| PRICE, Robert, Prof | Director | 2002-02-13 | 2023-11-20 |
| ROWE-JOSEPH, Gwenaelle | Director | 2019-06-05 | 2026-06-15 |
| SHUR, Jagdeep Singh, Dr | Director | 2015-02-09 | 2022-07-05 |
| WAYNE, Yvonne | Nominee Director | 2002-02-11 | 2002-02-11 |
| YOUNG, Paul Michael | Director | 2002-02-13 | 2007-09-30 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Aptargroup Uk Holdings Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2019-06-05 | Active |
| Sbms Enterprises Limited | Corporate entity | Shares 25–50% (as firm), Voting 25–50% (as firm) | 2016-04-06 | Ceased 2019-06-05 |
| Prof Robert Price | Individual | Appoints directors | 2016-04-06 | Ceased 2019-06-05 |
| Silures Limited | Corporate entity | Shares 50–75% (as firm), Voting 50–75% (as firm), Appoints directors (as firm) | 2016-04-06 | Ceased 2019-06-05 |
| Dr Jagdeep Singh Shur | Individual | Appoints directors | 2016-04-06 | Ceased 2019-06-05 |
| Mr Mark Rowland Clement | Individual | Shares 25–50%, Voting 25–50% | 2016-04-06 | Ceased 2016-04-06 |
Filing timeline
Last 20 of 103 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-09-24 | AA | accounts | Accounts with accounts type full | |
| 2026-06-19 | TM01 | officers | Termination director company with name termination date | |
| 2025-12-19 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-11-10 | CH01 | officers | Change person director company with change date | |
| 2025-10-20 | AP01 | officers | Appoint person director company with name date | |
| 2025-09-29 | AA | accounts | Accounts with accounts type medium | |
| 2025-07-22 | TM01 | officers | Termination director company with name termination date | |
| 2024-12-16 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-09-29 | AA | accounts | Accounts with accounts type full | |
| 2023-12-18 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-11-22 | TM01 | officers | Termination director company with name termination date | |
| 2023-09-29 | AA | accounts | Accounts with accounts type small | |
| 2022-12-16 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-12-16 | AD03 | address | Move registers to sail company with new address | |
| 2022-12-16 | AD02 | address | Change sail address company with new address | |
| 2022-08-26 | AA | accounts | Accounts with accounts type small | |
| 2022-07-19 | TM01 | officers | Termination director company with name termination date | |
| 2021-12-16 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-07-01 | AA | accounts | Accounts with accounts type small | |
| 2020-12-23 | CS01 | confirmation-statement | Confirmation statement with no updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 5
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.